HODGSON DAVID C 4

What Happened

• David C. Hodgson, a director of Royalty Pharma plc (RPRX), received an award of 4,545 restricted stock units (RSUs) on June 5, 2026. The units were granted at $0.00 (no cash paid) and therefore have a reported acquisition value of $0.
• This is an equity award (not a purchase or sale) under the company’s director equity plan and is typically a routine form of director compensation rather than a market trade.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-08 (appears timely).
• Grant type/code: A (award/grant); Shares granted: 4,545; Price per share: $0.00; Reported value: $0.
• Vesting: RSUs generally vest 100% on the earlier of the one-year anniversary of the grant or the annual meeting in the first calendar year following the grant, subject to the plan and award agreement.
• Beneficial ownership: The RSUs are held by Hodgson solely for the benefit of General Atlantic Service Company, L.P.; Hodgson disclaims beneficial ownership of the RSUs/underlying shares.
• Other holdings: Hodgson holds limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 79,476 Class A Ordinary Shares (reported separately).

Context

• This transaction is an equity compensation grant to a non-employee director and does not represent a market buy or sell signal. Grants like this are common for director compensation and typically vest over time.
• Because the reporting person disclaims beneficial ownership of these RSUs, they are not reported as directly beneficially owned by Hodgson until converted/vested and ownership is realized.